新的药物摄氏剂显示在治疗晚期乳腺癌、延长稳定期方面有重大好处。 New drug camizestrant shows significant benefits in treating advanced breast cancer, extending stable periods.

在治疗先进的荷尔蒙受体阳性、HER2-负性乳腺癌方面,一种新的药物,即卡梅斯特龙剂,已经显示出有希望的成果。 A new drug, camizestrant, has shown promising results in treating advanced hormone receptor-positive, HER2-negative breast cancer. 在第三阶段的SERENA-6试验中,卡梅斯特剂患者的癌症平均稳定16个月,而接受标准治疗的病人为9.2个月。 In the phase III SERENA-6 trial, patients on camizestrant had their cancer stable for an average of 16 months, compared to 9.2 months for those on standard treatment. 该药物与CDK4/6抑制剂相结合,将癌症发作的风险降低50%以上。 The drug, when combined with CDK4/6 inhibitors, reduced the risk of cancer progression by over 50%. 研究人员还利用血液测试检测早期抗药性迹象,指导及时的治疗调整。 Researchers also used blood tests to detect early signs of resistance, guiding timely treatment adjustments.